Will oral antithrombin agents replace warfarin?

Heart

Volumn 90, Issue 8, 2004, Pages 827-828

  Sinnaeve, P R ^b   Van De Werf, F J ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTIVITAMIN K; FONDAPARINUX; HEPARIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG SAFETY; EDITORIAL; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; HUMANS; THROMBOSIS; VITAMIN K; WARFARIN;

EID: 3442889161     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.030379     Document Type: Editorial

References (20)

1. Anon. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-57.
2. Bahit MC, Granger CB, Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment. Am Heart J 2002;143:205-16.
3. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-5.
4. Antman EM, Cohen M, Radley D, et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-8.
5. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002;360:109-13.
6. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-74.
7. Kottke-Marchant K, Bahit MC, Granger CB, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. Eur Heart J 2002;23:1202-12.
8. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
9. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12.
10. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-6.
11. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002;360:1441-7.
12. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
13. Wallentin L, Wilcox R, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after acute myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-97.
14. Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002;45:1757-66.
15. Jiao Y, Ubrich N, Marchand-Arvier M, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105:230-5.
16. Wong PC, Pinta DJ, Knabb RM. Nonpeptide factor Xa inhibitors: DPC423, a highly patent and orally bioavailable pyrazole antithrombotic agent. Cardiovasc Drug Rev 2002;20:137-52.
17. Hirayama F, Koshio H, Katayama N, et al. The discovery of YM-60828: a patent, selective and orally-bioavailable factor Xa inhibitor. Bioorg Med Chem 2002;10:1509-23.
18. Tanabe K, Morishima Y, Shibutani T, et al. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model. Thromb Haemost 1999;81:828-34.
19. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-24.
20. Simoons ML, Bobbink IW, Boland J, et al. A dose finding study of fondaparinox in patients with non-ST-segment elevation acute coronary syndromes: the PENTUA study. J Am Coll Card (in press.)